The tolerability of viscosupplementation: Low incidence and clinical management of local adverse events

Current Medical Research and Opinion

Volumn 19, Issue 7, 2003, Pages 575-580

  Waddell, David D ^a  

^a NONE   (United States)

Author keywords

Hyaluronans; Hylan; Knee; Osteoarthritis; Viscosupplementation

Indexed keywords

DICLOFENAC; HYALURONIC ACID; HYDROCODONE BITARTRATE PLUS PARACETAMOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARACETAMOL PLUS PENTAZOCINE; PARACETAMOL PLUS TRAMADOL; PENTAZOCINE; PLACEBO; TRAMADOL; UNCLASSIFIED DRUG;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; OSTEOARTHRITIS; PAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

HUMANS; HYALURONIC ACID; INCIDENCE; OSTEOARTHRITIS, KNEE; PAIN;

EID: 0142027151     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002243     Document Type: Review

References (50)

1. Friedman DM, Moore ME. The efficacy of intraarticular steroids in osteoarthritis: a double-blind study. J Rheumatol 1980;7:850-6
2. Valtonen EJ. Clinical comparison of triamcinolonehexacetonide and betamethasone in the treatment of osteoarthrosis of the knee-joint. Scand J Rheumatol Suppl 1981;41:1-7
3. Synvisc® (hylan G-F 20) Product Information. Genzyme Biosurgery, Inc, 2002
4. Waddell DD, Marino AA, Kolomytkin OV et al. Gap junctions in osteoarthritis. J Am Acad Orthop Surg 2002;3:574
5. Jackson DW, Evans NA, Thomas BM. Accuracy of needle placement into the intra-articular space of the knee. J Bone Joint Surg Am 2002;84-A:1522-7
6. Jones A, Regan M, Ledingham J et al. Importance of placement of intra-articular steroid injections. BMJ 1993;307:1329-30
7. Waddell D, Estey D, Bricker DC, Marsala A. Viscosupplementation under fluoroscopic control. Am J Med Sports 2001;4:237-41,249
8. Zardawi IM, Chan I. Synvisc perisynovitis. Pathology 2001;33:519-20
9. Sasaki M, Miyazaki Y, Takahashi T. Hylan G-F 20 induces delayed foreign body inflammation in guinea pigs and rabbits. Toxicol Pathol 2003;31:321-5
10. Larsen NE, Pollak CT, Reiner K, Leshchiner E, Balazs EA. Hylan gel biomaterial: dermal and immunologic compatibility. J Biomed Mater Res 1993;27:1129-34
11. Lussier A, Cividino AA, McFarlane CA et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996;23:1579-85
12. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998;20:410-23
13. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 1994;55:220-32
14. Adams ME. An analysis of clinical studies of the use of crosslinked hyaluronan, hylan, in the treatment of osteoarthritis. J Rheumatol 1993;20(Suppl 39):16-8
15. Dickson DJ, Hosie G, English JR. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J Clin Res 2001;4:41-52
16. Caborn DN, on behalf of the SYNVISC 901 Study Group. Efficacy and tolerability of hylan G-F 20 compared to intra-articular triamcinolone hexacetonide in patients with osteoarthritis of the knee in a randomized, evaluator-blinded study. Presented at the Annual Meeting for the Arthroscopy Association of North America 2003
17. Adams ME, Atkinson MH, Lussier AJ et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995;3:213-25
18. Raynauld JP, Torrance G, Band P et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17
19. Wobig M, Bach G, Beks P et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 1999;21:1549-62
20. Wobig M, Beks P, Dickhut A, Maier R, Vetter G. Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee. J Clin Rheumatol 1999;5:S24-S31
21. Puttick MP, Wade JP, Chalmers A, Connell DG, Rangno KK. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol 1995;22:1311-4
22. O'Hanlon D. Acute local reactions after intra-articular hylan for osteoarthritis of the knee. J Rheumatol 1996;23:945-6
23. Cooper C, Kirwan JR. The risks of local and systemic corticosteroid administration. Baillière's Clin Rheumatol 1991;4:305-32
24. Scott DL, Berry H, Capell H et al. The long-term effects of nonsteroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology 2000;39:1095-101
25. Gray RG, Gottlieb NL. Intra-articular corticosteroids. An updated assessment. Clin Orthop Rel Res 1983;235-63
26. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99
27. Laine A. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002;32(3 Suppl 1):25-32
28. Allen E, Krohn K. Adverse reactions to hylan GF-20. J Rheumatol 2000;27:6
29. Disla E, Infante R, Fahmy A, Karten I, Cuppari GG. Recurrent acute calcium pyrophosphate dihydrate arthritis intraarticular hyaluronic injection. Arthritis Rheum 1999;42:1302-3
30. Kroesen S, Schmid W, Theiler R. Induction of an acute attack of calcium pyrophosphate dihydrate arthritis by intra-articular injection of hylan G-F 20 (Synvisc). Clin Rheumatol 2000;19:147-9
31. Bernardeau C, Bucki B, Lioté F. Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystal. Ann Rheum Dis 2001;60:518-20
32. Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, Schumacher HR. Are there distinctive inflammatory flares after hylan G-F 20 intraarticular injections? J Rheumatol 2002;29:2611-4
33. Chen A, Desai P, Adler E, DiCesare PE. Granulomatous inflammation after hylan G-F 20 viscosupplementation of the knee: a report of 6 cases. J Bone Joint Surg 2002;84A:1142-7
34. Marino AA, Dunn S, Waddell DD. Comment on 'Granulomatous inflammation after hylan G-F 20 viscosupplementation of the knee: a report of 6 cases,' Chen et al. J Bone Joint Surg 2003; in press
35. Mont MA, Etienne G, Chen AL et al. Sequelae of hylan G-F 20 viscosupplementation of the knee. J Bone Joint Surg Am 2003;85-A:967-9
36. Luzar MJ, Altawil B. Psuedogout following intraarticular injection of sodium hyaluronate. Arthritis Rheum 1998;41:939-41
37. Maillefert JF, Hirschhorn P, Pascaud F, Piroth C, Tavernier C. Acute attack of chondrocalcinosis after an intraarticular injection of hyaluronan. Rev Rhum Engl Ed 1997;64:593-4
38. Grecomoro G, Martorana U, Di Marco C. Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo. Pharmatherapeutica 1987;5:137-41
39. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998;25:2203-12
40. Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatol 1999;38:602-7
41. Carrabba MP, Paresce E, Angelini M et al. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 1995;15:25-31
42. Leardini G, Franceschini M, Mattara L, Bruno R, Perbellini A. Intra-articular sodium hyaluronate (Hyalgan) in gonarthrosis. A controlled study comparing methylprednisolone acetate. Clin Trials J 1987;24:341-50
43. Henderson EB, Smith EC, Pegley F, Blake DR. Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis 1994;53:529-34
44. Pritchard CH, Sripada P, Bankes PF, Smith DG, Schneider D. A retrospective comparison of the efficacy and tolerability of sodium hyaluronate and hylan G-F 20 in the treatment of osteoarthritis of the knee. J Musculoskel Res 2002;6:197-205
45. Food and Drug Administration. Manufacturer and user facility device experience (MAUDE) database. Available at: www.access-data.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.cfm. Accessed on May 13, 2003
46. Surveillance Data Incorporated. Medical Claims Data. April 2003
47. Waddell DD, Cefalu CA, Bricker DC. An open-label study of a second course of hylan G-F 20 for the treatment of pain associated with knee osteoarthritis. Curr Med Res Opin 2003;19(6):499-507
48. Waddell DD, Estey DJ, Bricker D. Retrospective tolerance of hylan G-F 20 using fluoroscopically-confirmed injection and effectiveness of retreatment of knee osteoarthritis. Arthritis Rheum 2001;44:S48
49. Leopold SS, Warme WJ, Pettis PD, Shott S. Increased frequency of acute local reaction to intra-articular hylan GF-20 (Synvisc) in patients receiving more than one course of treatment. J Bone Joint Surg Am 2002;84-A:1619-23
50. Waddell DD. Local adverse events with more than one course of hylan G-F 20 therapy: comment on Leopold et al. J Bone Joint Surg 2003; in press